How many employees does Syndax Pharmaceuticals, Inc. have?

Syndax Pharmaceuticals, Inc. reported 298 employees for the fiscal year ending Dec 2025, in the annual report it filed on February 26, 2026. That is up 10.4% from a year earlier.

What is Syndax Pharmaceuticals, Inc.'s revenue per employee?

Syndax Pharmaceuticals, Inc. brought in $172M of revenue in fiscal Dec 2025, which is $578K per employee. That ranks 48 of 108 companies we track in Biotechnology, where the median is $459K.

Where do these numbers come from?

Employee counts and revenue are taken from each company's own annual report (Form 10-K). Open roles are counted from the company's public job board where we have matched one. Companies report headcount once a year, sometimes rounded, so small changes can be noise.

Company data

Syndax Pharmaceuticals, Inc. employees and revenue per employee

SNDX · Biotechnology · $1.51B market cap

Syndax Pharmaceuticals, Inc. had 298 employees at the end of fiscal Dec 2025, up 10.4% from a year earlier. Revenue for the year was $172M, up 627.8% from a year earlier, or $578K per employee. Revenue and headcount both grew, and revenue grew faster.

Employees

298

+10.4% YoY

Revenue

$172M

+627.8% YoY

Revenue / employee

$578K

Peer median $459K

Rank in industry

48 of 108

Biotechnology

Headcount against revenue

Both lines start at 100 in the first year we hold, so you can see which one grew faster.

EmployeesRevenueIndexed to 100 in Dec 2016

Hover a year for the numbers.

SNDX employees and revenue by fiscal year
Year ending	Employees	Revenue	Per employee	Staff YoY	Revenue YoY
Dec 2025	298	$172M	$578K	+10.4%	+627.8%
Dec 2024	270	$23.7M	$88K	—	—
Dec 2021	59	$140M	$2.37M	+37.2%	+9109.6%
Dec 2020	43	$1.5M	$35K	+22.9%	+0.0%
Dec 2019	35	$1.5M	$43K	-7.9%	+0.0%
Dec 2018	38	$1.5M	$40K	-13.6%	-28.0%
Dec 2017	44	$2.1M	$48K	+37.5%	+72.8%
Dec 2016	32	$1.2M	$38K	—	—

Open roles: we have not matched a verified job board for this company yet.

Employees, last six fiscal years

Revenue per employee, last six fiscal years

Syndax Pharmaceuticals, Inc. against similar companies

The closest industry peers by revenue, from Biotechnology.

Company	Employees	Revenue	Revenue / employee	Shape
MAZE Maze Therapeutics, Inc.	125	$168M	$1.34M	—
STOK Stoke Therapeutics, Inc.	170	$184M	$1.08M	Efficient growth
SNDX Syndax Pharmaceuticals, Inc.	298	$172M	$578K	Efficient growth
PHAT Phathom Pharmaceuticals, Inc.	371	$175M	$472K	Leaner
RGNX REGENXBIO Inc.	371	$170M	$459K	Efficient growth
RYTM Rhythm Pharmaceuticals, Inc.	414	$190M	$458K	Hiring ahead
MRVI Maravai LifeSciences Holdings, Inc.	435	$186M	$427K	Contracting
DNA Ginkgo Bioworks Holdings, Inc.	485	$170M	$351K	Contracting
BEAM Beam Therapeutics Inc.	511	$140M	$273K	Efficient growth

Every Healthcare company

Questions about Syndax Pharmaceuticals, Inc.

How many employees does Syndax Pharmaceuticals, Inc. have?: Syndax Pharmaceuticals, Inc. reported 298 employees for the fiscal year ending Dec 2025, in the annual report it filed on February 26, 2026. That is up 10.4% from a year earlier.
What is Syndax Pharmaceuticals, Inc.'s revenue per employee?: Syndax Pharmaceuticals, Inc. brought in $172M of revenue in fiscal Dec 2025, which is $578K per employee. That ranks 48 of 108 companies we track in Biotechnology, where the median is $459K.
Where do these numbers come from?: Employee counts and revenue are taken from each company's own annual report (Form 10-K). Open roles are counted from the company's public job board where we have matched one. Companies report headcount once a year, sometimes rounded, so small changes can be noise.

Free game

Think you can pick better than the S&P 500?

Pick 15 stocks, lock them in, and we score them against the index every trading day for ten years. Free, with a public leaderboard.

Enter the challenge

More data

Compare SNDX with the rest of the market

See who earns the most per employee, who is hiring, and who is cutting, across every company we track.

Leaderboard Healthcare

Source: employee counts and revenue as stated in Syndax Pharmaceuticals, Inc.'s annual reports (Form 10-K), latest filed February 26, 2026. This is data, not a recommendation to buy or sell SNDX.